Paul E. Kalb

The Caremark and Park doctrines require directors and managers of life sciences companies to address regulatory compliance proactively and vigorously.

Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.

Companies that fail to comply with regulatory guidelines make easy targets for investigators.